Patients in the European Union ( 74 patients ) and the United States ( 94 patients ) were randomly assigned , in a 1:1 ratio , to receive a subcutaneous implant containing either afamelanotide or placebo every 60 days ( a total of five implants in the European Union study and three in the U.S study ) .